Early studies have assessed the efficacy of CAR T therapy in GBM patients against targets including the epidermal growth factor receptor (EGFR) variant III (EGFRvIII) (5, 6), ERBB2/HER2 (7), and IL13Rα2 (8). The gene discussed is EGFR; the disease is glioblastoma.